Shares of Biocon Ltd. gained on Thursday, October 23, after the company said its subsidiary Biocon Biologics has received approval from Health Canada for a drug that treats a range of autoimmune conditions.

Biocon Biologics, a fully-integrated global biosimilars company, said it received approval for the Yesintek and Yesintek IV (ustekinumab injection), a biosimilar to Stelara IV on October 17.

The injections are indicated for the treatment of moderate to severe plaque psoriasis in adult patients and in paediatric patients (Age 6-17), active psoriatic arthritis in adults, moderately to severely active Crohn's disease and ulcerative colitis in adults —a range of debilitating autoimmune conditions that affect thousands of Canadians, the company said.

Yesintek will be available via the

See Full Page